The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

被引：487
|
作者：
Yuan, Min [1 ,2 ]
Huang, Li-Li [1 ,2 ]
Chen, Jian-Hua [1 ,3 ]
Wu, Jie [3 ,4 ]
Xu, Qing [1 ,2 ]
机构：
[1] Tongji Univ, Dermatol Hosp, Dept Oncol, Sch Med, Shanghai 200443, Peoples R China
[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Oncol, Sch Med, Shanghai 200072, Peoples R China
[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2019年 / 4卷 / 1期
基金：
中国国家自然科学基金;
关键词：
EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; ANTI-HER3; MONOCLONAL-ANTIBODY; NIVOLUMAB PLUS IPILIMUMAB; RECEPTOR GENE-MUTATIONS; RANDOMIZED PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; EGFR MUTATIONS;
D O I：
10.1038/s41392-019-0099-9
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.
引用
收藏
页数：14
相关论文
共 50 条
  • [31] Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead
    Ulahannan, D.
    Khalifa, J.
    Faivre-Finn, C.
    Lee, S. -M.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 2923 - 2931
  • [32] Necitumumab for the treatment of advanced non-small-cell lung cancer
    Diaz-Serrano, Asuncion
    Sanchez-Torre, Ana
    Paz-Ares, Luis
    FUTURE ONCOLOGY, 2019, 15 (07) : 705 - 716
  • [33] Emerging antiangiogenic therapies for non-small-cell lung cancer
    Blakely, Collin
    Jahan, Thierry
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1607 - 1618
  • [34] Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer
    Wolf, Emily
    Sacchi de Camargo Correia, Guilherme
    Li, Shenduo
    Zhao, Yujie
    Manochakian, Rami
    Lou, Yanyan
    VACCINES, 2025, 13 (02)
  • [35] Immunotherapy combinations emerging in non-small-cell lung cancer
    Chao, Yvonne L.
    Pecot, Chad V.
    IMMUNOTHERAPY, 2018, 10 (08) : 627 - 629
  • [36] Emerging targets in advanced non-small-cell lung cancer
    Valentino, Francesco
    Borra, Gloria
    Allione, Paolo
    Rossi, Lorena
    FUTURE ONCOLOGY, 2018, 14 (13) : 61 - 72
  • [37] Antiangiogenic therapies in non-small-cell lung cancer
    Alshangiti, A.
    Chandhoke, G.
    Ellis, P. M.
    CURRENT ONCOLOGY, 2018, 25 : S45 - S58
  • [38] Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC)
    Kumarakulasinghe, Nesaretnam Barr
    van Zanwijk, Nico
    Soo, Ross A.
    RESPIROLOGY, 2015, 20 (03) : 370 - 378
  • [39] Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
    Dolly, Saoirse O.
    Collins, Dearbhaile C.
    Sundar, Raghav
    Popat, Sanjay
    Yap, Timothy A.
    DRUGS, 2017, 77 (08) : 813 - 827
  • [40] Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
    Delahaye, Celia
    Figarol, Sarah
    Pradines, Anne
    Favre, Gilles
    Mazieres, Julien
    Calvayrac, Olivier
    CANCERS, 2022, 14 (11)
12345